SCHEMBL5860031

SCHEMBL5860031

COC(=O)[C@H](Cc1ccc([Sn](C)(C)C)cc1)NC(=O)C(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.45
MDM4 O15151 1/20 0.44
MDM2 Q00987 1/20 0.44
ALDH1A1 P00352 3/20 0.44
THRB P10828 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HDAC1 Q13547 6/20 0.43
HDAC6 Q9UBN7 6/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2520735 0.85 ATM (0.48) ATMMDM4MDM2ALDH1A1THRB
SCHEMBL12863003 0.85 MDM4 (0.60) ATMMDM4MDM2ALDH1A1THRB
SCHEMBL3536435 0.84 KLK5 (0.55) ATMMDM4MDM2
SCHEMBL5925862 0.84 KLK5 (0.55) ATMMDM4MDM2
SCHEMBL5263821 0.84 KLK5 (0.55) ATMMDM4MDM2
SCHEMBL28883302 0.83 NPSR1 (0.56) ATMMDM4MDM2ALDH1A1THRB
SCHEMBL28883406 0.83 NOS2 (0.55) ATMMDM4MDM2ALDH1A1THRB
SCHEMBL28883318 0.83 NOS2 (0.61) ATMMDM4MDM2ALDH1A1THRB
SCHEMBL6510996 0.83 LNPEP (0.49) ATMMDM4MDM2ALDH1A1THRB
SCHEMBL12863012 0.83 ATM (0.63) ATMMDM4MDM2ALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115768-B2 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20060074110-A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. 2006-04-06 US disclosed
EP-1144364-B1 MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARM INC (US) 2005-07-13 EP disclosed
US-20030134874-A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 GRANT FRANCINE S (US) 2003-07-17 US disclosed
US-6465513-B1 SUCH AS N-(ADAMANT-1-YLCARBONYL)-L-4-(N,N-DIMETHYLCARBAMYL-OXY)PHENYLALANINE; INFLAMMATORY DISEASES SUCH AS ASTHMA, AIDS DEMENTIA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS ELAN PHARMACEUTICALS, INC. 2002-10-15 US disclosed
EP-1144364-A2 MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2001-10-17 EP disclosed
WO-2000043354-A2 MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134874-A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, CD4 ATM 3908/4885MDM4 840/4885MDM2 3147/4885
US-20060074110-A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, CD4 ATM 3908/4885MDM4 840/4885MDM2 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.